Literature DB >> 24472734

Idiopathic venous thromboembolism: a potential surrogate for occult cancer.

W-S Chung1, C-L Lin2, W-H Hsu2, F-C Sung2, R-Y Li2, C-H Kao3.   

Abstract

BACKGROUND: Several studies have indicated an association between venous thromboembolism (VTE) and a subsequent diagnosis of cancer in Western countries. However, information is scant on subsequent cancer incidence after idiopathic VTE events in Asian people. Through a nationwide cohort study, we evaluated the cancer prevalence of VTE and new cancer incidence in patients after the first episode of idiopathic VTE.
METHODS: To conduct a nationwide population cohort study on VTE, we retrieved data from the Taiwan National Health Insurance Database from 1998 to 2008, including a 2-year follow-up period extending to the end of 2010. The occurrence of cancer in the cohort was also determined by accessing the Registry for Catastrophic Illness Patient Database.
RESULTS: A total of 45,242 patients had the newly diagnosed VTE from 1998 to 2008. The incidence of VTE increased with age. Among 28,243 idiopathic VTE patients, 1944 patients (6.89%) had a subsequent cancer diagnosis within 2 years of the first idiopathic VTE episode. The three most common newly diagnosed cancers after idiopathic VTE were lung cancer, liver cancer and colorectal cancer (18.3%, 12.3% and 10.9%, respectively). Male sex and advanced age are independent risk factors of having an underlying malignant disorder among patients diagnosed with idiopathic VTE.
CONCLUSION: Patients with symptomatic VTE without an identifiable risk factor have a 6.89% incidence of subsequent cancer diagnosis in Taiwan. An extensive screening for an occult cancer in an idiopathic VTE patient may be warranted.
© The Author 2014. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2014        PMID: 24472734     DOI: 10.1093/qjmed/hcu023

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  6 in total

Review 1.  Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Authors:  Hanno Riess; Cihan Ay; Rupert Bauersachs; Cecilia Becattini; Jan Beyer-Westendorf; Francis Cajfinger; Ian Chau; Alexander T Cohen; Alok A Khorana; Anthony Maraveyas; Marcos Renni; Annie M Young
Journal:  Oncologist       Date:  2018-04-12

2.  Incidence and risk of venous thromboembolism in patients following appendectomy: a nationwide cohort study.

Authors:  Wei-Sheng Chung; YuPei Chen; Weishan Chen; Cheng-Li Lin
Journal:  J Thromb Thrombolysis       Date:  2019-10       Impact factor: 2.300

3.  Bidirectional risk between venous thromboembolism and cancer in East Asian patients: synthesis of evidence from recent population-based epidemiological studies.

Authors:  Victor C Kok
Journal:  Cancer Manag Res       Date:  2017-12-05       Impact factor: 3.989

4.  Occult cancer in patients with deep-vein thrombosis in a general hospital at Mexico City: A pilot study.

Authors:  Christian O Ramírez-Serrano Torres; Edgardo Román-Guzmán; Carlos-Manuel Ortiz-Mendoza
Journal:  J Res Med Sci       Date:  2017-05-30       Impact factor: 1.852

5.  Variable predictors of acute pulmonary embolism recurrence with duration of follow-up.

Authors:  Yi-Lan Yang; Ping Yuan; Chuan-Yu Wang; Bigyan Pudasaini; Yuan Li; Yan-Zhe Yu; Qin-Hua Zhao; Lan Wang; Su-Gang Gong; Rong Jiang; Wen-Hui Wu; Jing He; Jian Guo; Ci-Jun Luo; Hong-Ling Qiu; Chang Chen; Jin-Ling Li; Jin-Ming Liu
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

6.  An Independent Risk of Gout on the Development of Deep Vein Thrombosis and Pulmonary Embolism: A Nationwide, Population-Based Cohort Study.

Authors:  Chien-Chung Huang; Po-Hao Huang; Jiunn-Horng Chen; Joung-Liang Lan; Gregory J Tsay; Hsiao-Yi Lin; Chun-Hung Tseng; Cheng-Li Lin; Chung-Yi Hsu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.